DK222 study for lung and bladder cancer
Part of Cancer, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a new imaging drug, DK222, to see how well it works in people with non-small cell lung cancer or bladder cancer who are about to start immunotherapy. It may help doctors see if the treatment is reaching the right targets.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have non-small cell lung cancer or bladder cancer that is confirmed by a biopsy.
- Your doctor must have already decided you should receive immunotherapy (anti-PD-1 or anti-PD-L1).
- Your tumor tissue must have been tested for PD-L1, or enough tissue must be available for testing.
- You must be able to walk and take care of yourself (performance status 0-2).
- Your kidneys, liver, and blood counts must be within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
This trial tests a new treatment that uses your own immune cells, called CAR-NK cells, modified to attack two proteins (Nectin-4 and HER2) often found on bladder cancer cells. It is for people whose cancer has spread or cannot be removed by surgery and has not responded to standard treatments like chemotherapy or immunotherapy.
This trial tests a new radioactive drug called 68Ga/177Lu-BRP-020063 in people with advanced solid tumors, especially bladder or breast cancer. The drug seeks out Nectin-4 on cancer cells, helping doctors see and potentially treat the tumors. The goal is to check that the drug is safe and tolerable.
This study tests whether a new drug called AK146D1, alone or combined with another drug called AK112, can help treat advanced urothelial carcinoma (a type of bladder cancer). The goal is to see if these drugs can shrink tumors and improve survival.
This trial tests a special injection (a radioactive tracer) that lights up PD-L1 in your tumors during a PET scan. It helps doctors see which tumors might respond to immunotherapy.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.